Dr Grant and Dr London are currently affiliated with the Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH. This study was performed at the Veterinary Medical Teaching Hospital at the University of California, Davis and The College of Veterinary Medicine, The Ohio State University, Columbus, OH. Presented at the 26th Annual Conference of the Veterinary Cancer Society, Callaway Gardens Resort, Pine Mountain, GA, October 19–22, 2006.
A Phase II Clinical Trial of Vinorelbine in Dogs with Cutaneous Mast Cell Tumors
Article first published online: 29 FEB 2008
Copyright © 2008 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 22, Issue 2, pages 388–393, March–April 2008
Total views since August 2010: 19
How to Cite
Grant, I.A., Rodriguez, C.O., Kent, M.S., Sfilgoi, G., Gordon, I. , Davis, G., Lord, L. and London, C.A. (2008), A Phase II Clinical Trial of Vinorelbine in Dogs with Cutaneous Mast Cell Tumors. Journal of Veterinary Internal Medicine, 22: 388–393. doi: 10.1111/j.1939-1676.2008.0051.x
- Issue published online: 29 FEB 2008
- Article first published online: 29 FEB 2008
- Submitted January 6, 2007; Revised March 14, 2007; Accepted October 17, 2007. Correction added after online publication February 29, 2008: Addition of authors G. Sfiligoil, I. Gordon, and G. Davis.
- Vinca alkaloid
Background: Few effective drugs are available to treat dogs with locally aggressive or metastatic mast cell disease.
Hypothesis: Vinorelbine, a semisynthetic derivative of vinblastine, is an effective drug for the treatment of canine mast cell tumors (MCT).
Animals: Twenty-four dogs with cutaneous MCT.
Methods: Dogs with at least 1 measurable, cytologically confirmed, and previously untreated cutaneous MCT received a single treatment with vinorelbine at the previously established dosage of 15 mg/m2 IV. Tumor measurements and CBC were evaluated before and 7 days after treatment. Adverse events were graded according to Veterinary Cooperative Oncology Group (VCOG) guidelines.
Statistics: Data were accrued in accordance with a Simon's 2-stage design with a noninteresting response rate of .05, a target response of .25, and α and β values of .10.
Results: Three of 24 dogs (13%) had a response to treatment, including 1 measurable complete response and 1 measurable partial response. The 3rd dog had microscopic complete response to treatment with stable measurable disease. Twenty other dogs (83%) had stable disease and 1 dog (4%) had progressive disease. Neutropenia occurred in 13 dogs (54%) (grade 1, n = 4; grade 3, n = 6; grade 4, n = 3). Gastrointestinal toxicity occurred in 11 dogs (46%) (anorexia: grade 1, n = 3; grade 2, n = 1; grade 3, n = 1; diarrhea: grade 1, n = 2; grade 3, n = 1; vomiting: grade 1, n = 5; grade 3, n = 1).
Conclusions and Clinical Importance: Vinorelbine was associated with an overall response rate of 13% and a high prevalence of neutropenia. Additional studies are indicated to determine if repeated dosing of vinorelbine or combination of vinorelbine with other drugs increases the observed biologic activity against canine MCT.